alexa Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.


Immunotherapy: Open Access

Author(s): Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J

Abstract Share this page

PURPOSE: An antibody-drug conjugate consisting of monomethyl auristatin E (MMAE) conjugated to the anti-CD30 monoclonal antibody (mAb) cAC10, with eight drug moieties per mAb, was previously shown to have potent cytotoxic activity against CD30(+) malignant cells. To determine the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates containing different drug-mAb ratios in vitro and in vivo. EXPERIMENTAL DESIGN: Coupling MMAE to the cysteines that comprise the interchain disulfides of cAC10 created an antibody-drug conjugate population, which was purified using hydrophobic interaction chromatography to yield antibody-drug conjugates with two, four, and eight drugs per antibody (E2, E4, and E8, respectively). Antibody-drug conjugate potency was tested in vitro against CD30(+) lines followed by in vivo xenograft models. The maximum-tolerated dose and pharmacokinetic profiles of the antibody-drug conjugates were investigated in mice. RESULTS: Although antibody-drug conjugate potency in vitro was directly dependent on drug loading (IC(50) values E8
  • To read the full article Visit
  • DOI: 10.1158/1078-0432.CCR-04-0789
  • Open Access
  • This article was published in Clin Cancer Res and referenced in Immunotherapy: Open Access

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Relevant Topics

    Peer Reviewed Journals
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version